Cytokine release syndrome (CRS) represents an on-target effect of chimeric antigen receptor (CAR) T-cell therapy and consists of a systemic inflammatory response due to a massive cytokine release, including IL-6, GM-CSF, and interferon-γ, following the in vivo activation of CAR T-cells (21, 22). This evidence concerns the gene CSF2 and congenital rubella syndrome.